Journal of Oncology / 2021 / Article / Tab 3 / Research Article
UGT1A1 Polymorphism for Irinotecan Dose Escalation in Patients with BRAF -Mutated Metastatic Colorectal Cancer Treated with First-Line Bevacizumab and FOLFIRITable 3 Toxicities of 17 patients with mCRC.
Adverse effect Grades 1–2 (%) Grade ≥ 3 (%) Any grade (%) Anemia 13 (76.5) 0 (0) 13 (76.5) Fatigue 10 (58.8) 0 (0) 10 (58.8) Nausea 8 (47.1) 1 (5.9) 9 (52.9) Neutropenia 8 (47.1) 1 (5.9) 9 (52.9) Hair loss 8 (47.1) 0 (0) 8 (47.1) Thrombocytopenia 6 (35.3) 0 (0) 6 (35.3) Abnormal liver function 6 (35.3) 0 (0) 6 (35.3) Vomiting 3 (17.6) 1 (5.9) 4 (23.5) Acute kidney injury 3 (17.6) 0 (0) 3 (17.6) Diarrhea 2 (11.8) 0 (0) 2 (11.8) Paresthesia 2 (11.8) 0 (0) 2 (11.8)